Physician profile
Michael E Herman
NPI 1831179290
$130,579.35
in general payments reported to CMS, 2019-2025
32 companies · $51K in 2025
The $51K reported for 2025 was more than what 97% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $35K · 2020: $16K · 2021: $1,133 · 2022: $557 · 2023: $670 · 2024: $26K · 2025: $51K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Travel and Lodging: $4,319 · Food and Beverage: $4,049.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $69,649.50 |
| Travel and Lodging | $4,319.36 |
| Food and Beverage | $4,048.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $68,009.21 | 2024-2025 | Rezdiffra |
| Gilead Sciences, INC. | $25,255.99 | 2019-2025 | |
| Intercept Pharmaceuticals, INC. | $24,682.66 | 2019-2021 | |
| Phathom Pharmaceuticals, INC. | $8,092.13 | 2024-2025 | Voquezna |
| Abbvie INC. | $1,912.05 | 2019-2025 | |
| Shionogi INC | $781.33 | 2019 | |
| Janssen Biotech, INC. | $380.19 | 2019-2024 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $273.76 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $222.97 | 2019-2025 | Gattex |
| Janssen Scientific Affairs, LLC | $127.03 | 2024 | |
| Pfizer INC. | $91.40 | 2024-2025 | |
| Aimmune Therapeutics, INC. | $77.96 | 2023-2025 | Zenpep |
| Merck Sharp & Dohme LLC | $73.91 | 2021-2024 | Dificid |
| Braintree Laboratories, INC. | $69.93 | 2019-2023 | Sutab |
| Celgene Corporation | $68.82 | 2023 | Zeposia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $62.99 | 2019 | |
| Ironwood Pharmaceuticals, INC | $56.26 | 2020-2024 | Linzess |
| Ipsen Biopharmaceuticals, INC | $55.95 | 2025 | Iqirvo |
| Ucb, INC. | $51.87 | 2019-2020 | |
| Lilly USA, LLC | $38.51 | 2024-2025 | Omvoh |
| Allergan, INC. | $34.11 | 2019-2020 | |
| Genzyme Corporation | $26.55 | 2024 | |
| Albireo Pharma, INC. | $23.67 | 2023 | Bylvay |
| Alnylam Pharmaceuticals INC. | $22.63 | 2024 | Givlaari |
| Regeneron Healthcare Solutions, INC. | $20.95 | 2025 | Dupixent |
| Novo Nordisk INC | $19.56 | 2025 | Wegovy |
| Vivus LLC | $17.00 | 2021 | |
| Concordia Pharmaceuticals INC. | $15.37 | 2019 | |
| Medtronic, INC. | $14.59 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Herman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.